Research Topics
Genomes and Genes | Paul RussoSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Open partial nephrectomy. Personal technique and current outcomesPaul Russo
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Arch Esp Urol 64:571-93. 2011..Widespread education and training in kidney preserving surgical strategies is essential going forward...
Oncological and renal medical importance of kidney-sparing surgeryPaul Russo
Weill Medical College, Cornell University, 1275 York Avenue, New York, NY 10021, USA
Nat Rev Urol 10:292-9. 2013..Despite these important advances in understanding, which support the use of partial nephrectomy for the treatment of small renal masses, the technique remains underused...
Functional preservation in patients with renal cortical tumors: the rationale for partial nephrectomyPaul Russo
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Urol Rep 9:15-21. 2008..73m2, a level of significant CKD, is 95% after PN, but only 64% after RN. RN should be reserved for patients with massive renal tumors in whom PN is not an option. Increased training in PN and its wider application is essential...
Multi-modal treatment for metastatic renal cancer: the role of surgeryPaul Russo
Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
World J Urol 28:295-301. 2010....
Renal cryoablation: a new treatment in need of careful clinical investigationPaul Russo
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Oncol 3:286-7. 2006
Renal tumours: developing understanding leads to developments in surgical treatmentPaul Russo
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 97:9-10. 2006
Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomyPaul Russo
Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
Urol Clin North Am 35:679-86; viii. 2008..Once effective systemic agents are developed, both metastasectomy and cytoreductive nephrectomy will play greater roles in consolidating clinical responses...
Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomyPaul Russo
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Urol 1:26-30. 2004..Despite these advances, the prognosis for patients with metastatic RCC is poor. Studies that examine combinations of surgery and systemic therapy aim to improve survival in this high-risk group...
Open partial nephrectomy: an essential contemporary operationPaul Russo
Department of Urology of Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Urol 3:2-3. 2006
The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumorsPaul Russo
Department of Surgery, Urology Service, Weill Cornell College of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Urol Clin North Am 35:635-43; vii. 2008..The overzealous use of radical nephrectomy for small renal tumors must now be considered detrimental to the long-term health and safety of the patient with a small renal cortical tumor...
Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancerPaul Russo
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
ScientificWorldJournal 7:768-78. 2007..This surgical experience provides a contemporary foundation as new targeted therapeutic agents are integrated into the neoadjuvant or adjuvant treatment of locally advanced and metastatic renal cancer...
Partial nephrectomy achieves local tumor control and prevents chronic kidney diseasePaul Russo
Memorial Sloan Kettering Cancer Center, Department of Surgery, Urology Service, 1275 York Avenue, NY, 10021, USA
Expert Rev Anticancer Ther 6:1745-51. 2006....
Survival rates after resection for localized kidney cancer: 1989 to 2004Paul Russo
Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer 113:84-96. 2008....
Open partial nephrectomy: an essential operation with an expanding rolePaul Russo
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
Curr Opin Urol 17:309-15. 2007..To describe the rationale for expanding the role of partial nephrectomy in the treatment of renal cortical tumors...
Partial nephrectomy: the rationale for expanding the indicationsPaul Russo
Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Ann Surg Oncol 9:680-7. 2002..We report preliminary results of partial nephrectomy for renal tumors of > or =4 cm in 39 patients with the intent of extending the indications for kidney-sparing surgery...
Oncological outcomes of partial nephrectomy for renal carcinoma greater than 4 cmPaul Russo
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Curr Opin Urol 21:362-7. 2011..To provide the clinical evidence and benefits of performing partial nephrectomy for renal tumors greater than 4 cm...
Localized renal cell carcinomaP Russo
Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Treat Options Oncol 2:447-55. 2001..Whether these new approaches to localized renal tumors will supplement or replace current surgical techniques will depend on the findings of carefully designed and controlled clinical trials...
Urinary diversion after total pelvic exenteration for rectal cancerP Russo
Department of Surgery, Urology Services, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Ann Surg Oncol 6:732-8. 1999..We review a 10-year Memorial Sloan-Kettering Cancer Center experience with urinary diversion in this setting...
The role of surgery in the management of early-stage renal cancerPaul Russo
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Medical College, Cornell University, 1275 York Avenue, New York, NY 10021, USA
Hematol Oncol Clin North Am 25:737-52. 2011..In this article, the optimum approach to the surgical management of localized renal tumors and its impact on renal function are discussed...
Salvage radical prostatectomy after radiation therapy and brachytherapyP Russo
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Endourol 14:385-90. 2000..Perioperative complications are substantial, with urinary incontinence rates of 40% to 50% and rectal injury rates of 10% to 15%. Long-term disease-free survival rates of 30% to 40% can be expected...
Metastatic renal cell carcinoma risk according to tumor sizeR Houston Thompson
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 182:41-5. 2009..We present our experience with renal cell carcinoma. We evaluated the association between tumor size and the metastasis risk in a large patient cohort...
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experienceAtreya Dash
Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 113:2471-7. 2008..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
Tumor size is associated with malignant potential in renal cell carcinoma casesR Houston Thompson
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 181:2033-6. 2009..We evaluated our experience with renal cortical tumors to determine whether tumor size is associated with malignant histology and/or nuclear grade...
Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinomaAri Adamy
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 185:433-8. 2011..We analyzed characteristics in patients with recurrent renal cell carcinoma 5 years or later after nephrectomy and determined predictors of survival after recurrence...
Bladder cancer as a prognostic factor for upper tract transitional cell carcinomaMichael Mullerad
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 172:2177-81. 2004..CONCLUSIONS: This study demonstrates that a history of BTCC (invasive or superficial) has an adverse effect on the prognosis of patients diagnosed with UTTCC independent of primary tumor stage...
Renal cell carcinoma in young and old patients--is there a difference?R Houston Thompson
Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 180:1262-6; discussion 1266. 2008..We reviewed our experience with young patients with renal cell carcinoma and compared them to their older counterparts...
Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC)Jonathan L Silberstein
Department of Surgery, Urology Service Departments of Epidemiology and Biostatistics Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 110:1276-82. 2012..When complications were sustained, patients were less likely to receive systemic therapy in a timely fashion. These observations may influence the timing or patient selection for surgery or systemic therapy...
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrenceScott E Eggener
Genitourinary Oncology Service, Division of Solid Tumor Oncology and Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
J Clin Oncol 24:3101-6. 2006..CONCLUSION: At disease recurrence after nephrectomy for localized disease, a scoring system based on objective clinical and laboratory data provides meaningful risk stratification for both patient counseling and clinical trial entry...
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced diseaseAna M Molina
Department of Medicine, Genitourinary Oncology Service, Weil Medical College of Cornell University, New York, NY, USA
Am J Clin Oncol 34:454-9. 2011..Sarcomatoid variant is a spindle cell phenotype of renal cell carcinoma (RCC), which is associated with a poor prognosis. We reviewed outcomes of systemic therapy for metastatic, sarcomatoid-variant RCC...
Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selectionJeffrey M Holzbeierlein
Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 E. 68th Street, New York, NY 10021, USA
J Urol 172:878-81. 2004..CONCLUSIONS: In highly selected patients with invasive bladder cancer, partial cystectomy offers acceptable outcomes. Concomitant CIS and presence of metastases to regional lymph nodes predict advanced recurrence...
Treatment outcome for metastatic papillary renal cell carcinoma patientsEllen A Ronnen
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer 107:2617-21. 2006..Further understanding of the genetics and molecular biology and subtypes involved may provide the basis for more effective agents. Treatment with targeted therapies or other experimental agents is warranted...
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinomaScott E Eggener
Department of Urology and Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 180:873-8; discussion 878. 2008..We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma...
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort studyWilliam C Huang
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Lancet Oncol 7:735-40. 2006..Radical nephrectomy is a significant risk factor for the development of chronic kidney disease and might no longer be regarded as the gold standard treatment for small, renal cortical tumours...
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo studyHikmat A Al-Ahmadie
Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Am J Surg Pathol 35:949-61. 2011..Both extent and patterns must be considered for a definitive diagnosis...
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinomaStephen D W Beck
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Ann Surg Oncol 11:71-7. 2004..Knowledge of renal cortical tumor histological subtype is critical for projecting prognosis, tailoring follow-up strategies, and designing clinical trials...
Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institutionChristopher G Przybycin
Department of Pathology, Urology Service, Memorial Sloan Kettering Cancer Center New York, NY 10065, USA
Am J Surg Pathol 35:962-70. 2011..On the basis of this long follow-up on a large number of cases, chromophobes seem to have better clinical outcomes than those reported for clear cell and papillary RCCs...
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinomaMaximiliano Sorbellini
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Urol 173:48-51. 2005..This nomogram may be useful for patient counseling, clinical trial design and effective patient followup strategies...
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladderGuido Dalbagni
Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:2729-34. 2006..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
Complications after radical and partial nephrectomy as a function of ageWilliam T Lowrance
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 183:1725-30. 2010..We determined if the association of age and perioperative outcomes differed between nephrectomy types...
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tractMatthew D Galsky
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 69:255-9. 2007..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
Positive surgical margins at partial nephrectomy: predictors and oncological outcomesOfer Yossepowitch
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 179:2158-63. 2008..We combine data from 2 tertiary care intuitions, and report predictors of positive surgical margins and long-term oncological outcomes for patients with positive surgical margins...
Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomyNicholas E Power
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Urology 79:821-5. 2012..To evaluate intravenous mannitol during minimally invasive partial nephrectomy (PN) by comparing the renal function outcomes of the patients who received it versus those who did not...
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimetersPreston C Sprenkle
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Eur Urol 61:593-9. 2012..Indications for partial nephrectomy (PN) in the treatment of renal cell carcinoma are evolving, particularly for larger, more complex tumors...
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodiesHikmat A Al-Ahmadie
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Am J Surg Pathol 32:377-82. 2008..Therefore, similar to the clone M75, NB100-417 can be used as a diagnostic and potentially a prognostic marker in CRCC, with the advantage of its commercial availability...
Recovery of renal function after open and laparoscopic partial nephrectomyAri Adamy
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Eur Urol 58:596-601. 2010..Although oncologic outcomes appear to be similar after laparoscopic partial nephrectomy (LPN) and open partial nephrectomy (OPN), data on renal function are lacking...
Significance of peritumoral vascularity on CT in evaluation of renal cortical tumorJingbo Zhang
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Comput Assist Tomogr 31:717-23. 2007..To investigate whether the presence and degree of peritumoral vascularity may provide any diagnostic information regarding the histological subtypes of renal tumors...
Phase II trial of lenalidomide in patients with metastatic renal cell carcinomaPremal H Patel
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 26:273-6. 2008..Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial...
Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumorsCheryl T Lee
Department of Urology, University of Michigan, 1500 E Medical Center Drive, Box 0330, Ann Arbor, MI 49109, USA
Urol Oncol 21:179-84. 2003..It may be reasonable to target RCC patients displaying altered bcl-2 levels for molecular therapies, such as anti-bcl2, should metastatic disease develop...
Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sexMark E Snyder
Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Urol 176:2391-5; discussion 2395-6. 2006..13). CONCLUSIONS: A significant number (16.4%) of benign lesions less than 7 cm in radiological diameter were operated on based on suspicious preoperative imaging. Women had almost twice the likelihood of having a benign lesion...
Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resectionMichael E Karellas
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 103:160-4. 2009..To examine the effect of radical nephrectomy (RN) with adjacent organ and structure resection on survival, as invasion of adjacent organs in patients with renal cell carcinoma (RCC) is rare...
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinomaRobert J Motzer
Geritourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 22:454-63. 2004..To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy...
Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypesHebert Alberto Vargas
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C 278E, New York, NY 10065, USA
Radiology 264:779-88. 2012..To investigate the use of quantitative multiphasic contrast material-enhanced magnetic resonance (MR) imaging in differentiating between common benign and malignant histologic subtypes of renal cortical tumors...
Perioperative clinical thromboembolic events after radical or partial nephrectomyJoseph A Pettus
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 68:988-92. 2006..Thromboembolic events are rare but are more likely to occur in patients with coronary artery disease, cardiac arrhythmia, prior DVT, Stage 3 or 4 tumors, or a large estimated blood loss...
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinomaDavid J Gallagher
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer 115:5193-201. 2009..The objective of this study was to evaluate the feasibility and survival impact of adjuvant, sequential chemotherapy in patients with high-risk UC...
Renal oncocytosis: management and clinical outcomesAri Adamy
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 185:795-801. 2011..We describe our experience with renal oncocytosis, focusing on management and outcomes...
Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumorsJoseph A Pettus
Department of Urology, Wake Forest University Baptist Hospital, Medical Blvd, Winston Salem, NC 27157, USA
Mayo Clin Proc 83:1101-6. 2008..To evaluate the effect of baseline renal function and comorbidity index on survival in patients with renal tumors...
Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumoursEric O Kwon
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 99:286-9. 2007....
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumorsR Houston Thompson
Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55902, USA
J Urol 182:2601-6. 2009..We evaluated survival in patients with 4 to 7 cm renal tumors in a bi-institutional collaboration...
Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal functionOfer Yossepowitch
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:1339-43; discussion 1343. 2006..Longer clamping time is particularly detrimental in patients with a solitary kidney but it does not appear to influence long-term renal function. Patients of advanced age may be less likely to recover from acute ischemic renal injury...
Radical nephrectomy with vena caval thrombectomy: a contemporary experienceMatthew G Kaag
Urology Service and Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 107:1386-93. 2011..To report on the contemporary Memorial Sloan-Kettering Cancer Center experience with radical nephrectomy and vena caval thrombectomy...
Preoperative nomogram predicting 12-year probability of metastatic renal cancerGanesh V Raj
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 179:2146-51; discussion 2151. 2008..We developed a predictive model that could be used in the preoperative setting...
Contemporary use of partial nephrectomy at a tertiary care center in the United StatesR Houston Thompson
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 181:993-7. 2009..The use of partial nephrectomy for renal cortical tumors appears unacceptably low in the United States according to population based data. We examined the use of partial nephrectomy at our tertiary care facility in the contemporary era...
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinomaBeverly Drucker
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 21:341-5. 2003..At the dose and schedule used in this trial, the lack of antitumor activity associated with ZD1839 does not support further study in patients with metastatic RCC...
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinomaDarren R Feldman
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Genitourin Cancer 6:25-30. 2008..In this study, the efficacy and toxicity of pegylated IFN was assessed in patients with metastatic renal cell carcinoma (mRCC)...
Partial nephrectomy for selected renal cortical tumours of ≥ 7 cmMichael E Karellas
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 106:1484-7. 2010....
Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survivalJ James Bruno
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
BJU Int 97:933-8. 2006..The presence of synchronous metastasis and nonoperative therapy are related to these low survival rates. However, if there is no metastatic disease, complete surgical resection of LRs is associated with improved survival...
Prognostic impact of histological subtype on surgically treated localized renal cell carcinomaPatrick E Teloken
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 182:2132-6. 2009..We evaluated our experience with tumor histology in patients with localized renal cell carcinoma...
Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologiesWilliam T Lowrance
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 105:16-20. 2010....
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size?Jordan M Kurta
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 103:24-7. 2009..To evaluate the difference between radiographic size on computed tomography (CT) and the pathological size of renal tumours, in contemporary patients...
Sunitinib therapy in renal cell carcinomaPaul Russo
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 101:1339-42. 2008
Phase II trial of bortezomib for patients with advanced renal cell carcinomaG Varuni Kondagunta
Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:3720-5. 2004..Efforts to identify the molecular profile associated with clinical response or combination therapy with interferon alfa or other novel agents, may be considered...
Long-term follow-up of bilateral sporadic renal tumorsManish I Patel
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 61:921-5. 2003..Conventional clear cell histology was the most common histologic subtype; concordance among tumors was found to be 76%. DFS rates comparable to those of unilateral tumors can be obtained by using combinations of PN and RN...
Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histologyFarhang Rabbani
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 171:1057-61. 2004..We determined the prognostic significance of renal vein or inferior vena caval (IVC) extension in patients with nonmetastatic renal cell carcinoma (RCC) or oncocytoma undergoing surgery...
Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrenceOfer Yossepowitch
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Urol 169:177-81. 2003....
Tumor location does not affect long-term renal function after partial nephrectomyJoseph A Pettus
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 69:1059-63. 2007..To study the effect of central tumor location on the glomerular filtration rate (GFR) after partial nephrectomy for renal cortical tumor...
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trialChaitanya R Divgi
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lancet Oncol 8:304-10. 2007..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
A postoperative prognostic nomogram for renal cell carcinomaM W Kattan
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 166:63-7. 2001..The nomogram may be useful for patient counseling, clinical trial design and patient followup planning...
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complicationsKarim Touijer
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Eur Urol 57:214-22. 2010....
Solid renal cortical tumors: differentiation with CTJingbo Zhang
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room C278D, New York, NY 10021, USA
Radiology 244:494-504. 2007..To retrospectively determine if solid renal cortical tumors can be differentiated on computed tomographic (CT) images on the basis of their morphologic features and enhancement patterns...
Hereditary and familial kidney cancerJonathan A Coleman
Department of Surgery Urology Division, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Curr Opin Urol 19:478-85. 2009..The purpose of this review is to familiarize the reader with the known heritable forms of kidney cancer, the recent advances in the field and their impact on patient management...
Mode of presentation of renal cell carcinoma provides prognostic informationCheryl T Lee
Department of Urology, University of Michigan Hospitals, 1500 E Medical Center Drive, Box 0330, Ann Arbor, MI 48109, USA
Urol Oncol 7:135-40. 2002..Previous small series have suggested a prognostic benefit for incidental presentation. This study utilizes a large contemporary patient cohort to examine patterns of RCC presentation and their clinical implications...
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladderGuido Dalbagni
Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 20:3193-8. 2002..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
Natural history of chronic renal insufficiency after partial and radical nephrectomyJames McKiernan
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 59:816-20. 2002..008). CONCLUSIONS: When controlled for preoperative risk factors for renal insufficiency, patients undergoing RN are at a greater risk of chronic renal insufficiency than a similar cohort of patients undergoing PN...
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histologyRobert J Motzer
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2376-81. 2002..To define outcome data for patients with metastatic renal cell carcinoma (RCC) with histology other than clear-cell type, including collecting duct (or medullary carcinoma), papillary, chromophobe, and unclassified histologies...
Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factorsFarhang Rabbani
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2370-5. 2002....
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaRobert J Motzer
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 20:289-96. 2002..The data can be applied to design and interpretation of clinical trials of new agents and treatment programs against this refractory malignancy...
Evaluation of renal masses with contrast-enhanced ultrasound: initial experienceScott Gerst
Department of Radiology, Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, 300 E 66th St, Rm 705, New York, NY 10065, USA
AJR Am J Roentgenol 197:897-906. 2011..This prospective study was performed to determine whether preoperative IV microbubble contrast-enhanced ultrasound can be used to differentiate indolent and benign renal tumors from more aggressive clear cell carcinoma...
Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma casesAndrew Feifer
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 185:37-42. 2011..To validate this presumed equivalence we compared patients with isolated muscular venous branch invasion to those with renal vein invasion and those with no confirmed vascular invasion...
Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumorAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 171:1474-7. 2004..In a cohort of patients who underwent exploratory laparotomy for unsuspected metastatic GCT we determined the impact of this surgery on morbidity, therapeutic delay and cancer therapy...
Incidental angiomyolipoma resected during renal surgery for an enhancing renal massRyan K Berglund
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 104:1650-4. 2009....
A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probesVivian E Strong
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Surg Endosc 22:386-91. 2008..These PET probes are handheld, allowing for real-time evaluation of cancer using a tool that provides surgeons with better intraoperative assessment of tumor sites...
Impact of body mass index on survival of patients with surgically treated renal cell carcinomaS Machele Donat
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Urol 175:46-52. 2006..We evaluated the impact of BMI and other clinical/pathological characteristics on survival in patients with RCC treated with radical or partial nephrectomy...
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cmAtreya Dash
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 97:939-45. 2006..To compare the outcomes of patients who had a elective partial nephrectomy (PN) or radical nephrectomy (RN) for clear cell renal cell carcinoma (RCC) of 4-7 cm...
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinomaSatish K Tickoo
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 177:1258-63. 2007..We investigated the hypoxia inducible pathway marker immunohistochemical expression profile, and any potential therapeutic implications that such expression may have, in these tumors...
Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillanceF Rabbani
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 19:94-100. 2001....
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cellsV M Richon
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 57:2789-98. 1997....
A case of port-site recurrence and locoregional metastasis after laparoscopic partial nephrectomyTimothy A Masterson
Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Urol 5:345-9. 2008..5 cm right renal mass, pathologically confirmed as type 2 papillary renal cell carcinoma (RCC). Two years later he was referred to a specialist oncology center after routine follow-up raised suspicion for metastatic disease...
Long-term response with sunitinib for metastatic renal cell carcinomaEllen A Ronnen
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 68:672.e19-20. 2006..This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma...
Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survivalLee Richstone
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 171:615-20. 2004..3% frequency of multifocal renal cortical tumors and a 3.5% frequency of clinically unsuspected multifocal tumors. Multifocality had no apparent effect on recurrence or survival in patients who underwent radical nephrectomy...
A comparison of hospital-based charges following partial and radical nephrectomyJ M McKiernan
Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, C-1064, New York, NY 10021, USA
Urol Oncol 7:3-6. 2002..No difference was found in the complication rate for these procedures (p > .05). CONCLUSION: Hospital-based charges for radical and partial nephrectomy are similar at when performed at a tertiary care referral center...
Urologic complications of major pelvic surgeryJ R Wagner
Department of Urology, Beth Israel Medical Center, New York, New York, USA
Semin Surg Oncol 18:216-28. 2000..An understanding of the prevention, recognition, and treatment of urologic complications is important for every surgeon performing major pelvic surgery...
